EGRX · Eagle Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $316.61M | $171.55M | $187.80M | $195.89M | $189.48M | $236.71M |
| Cost of Revenue | $85.46M | $31.53M | $33.65M | $47.89M | $35.78M | - |
| Gross Profit | $231.15M | $140.02M | $154.16M | $151.40M | $153.70M | - |
| R&D | $34.09M | $51.27M | $30.79M | $36.81M | $44.42M | $32.61M |
| SG&A | $106.63M | $75.32M | $78.60M | $76.37M | $60.51M | $71.42M |
| Total Operating Expenses | $235.65M | $168.78M | $154.85M | $162.72M | $176.70M | $162.72M |
| D&A | $646.0K | $764.0K | $872.0K | $972.0K | $1.16M | $932.0K |
| Operating Income | $80.96M | $2.77M | $32.95M | $21.82M | $36.62M | $73.99M |
| Interest Expense | $4.04M | $1.64M | $2.58M | $2.69M | $2.74M | $1.14M |
| Income Tax | $25.79M | $4.08M | $10.69M | $7.68M | $2.13M | $21.00M |
| Net Income | $35.64M | ($8.63M) | $11.99M | $14.31M | $31.90M | $51.94M |
| EPS - Basic | $2.76 | ($0.66) | $0.89 | $1.04 | $2.16 | $3.44 |
| EPS - Diluted | $2.73 | ($0.66) | $0.87 | $1.01 | $2.09 | $3.27 |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $55.32M | $97.66M | $103.16M | $109.78M | $78.79M | $114.66M |
| Accounts Receivable | $72.44M | $41.15M | $51.12M | $48.00M | $66.49M | $53.82M |
| Inventory | $47.79M | $21.91M | $8.07M | $6.57M | $8.30M | $5.12M |
| Accounts Payable | $18.99M | $16.43M | $6.27M | $5.46M | $9.92M | $11.98M |
| Current Assets | $188.75M | $172.61M | $166.06M | $179.45M | $163.84M | $188.70M |
| Total Assets | $406.16M | $253.73M | $253.19M | $254.55M | $238.60M | $270.06M |
| Current Liabilities | $111.09M | $74.38M | $38.09M | $38.82M | $39.69M | $47.30M |
| Long-term Debt | $56.22M | $0 | $25.14M | $33.56M | $38.16M | $42.91M |
| Total Liabilities | $172.60M | $77.28M | $67.18M | $77.84M | - | - |
| Stockholders' Equity | $233.56M | $176.45M | $186.01M | $179.17M | $160.76M | $179.14M |
| Retained Earnings | $111.50M | $75.86M | $84.49M | $72.50M | $58.19M | $26.28M |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $50.70M | $28.22M | $49.50M | $55.99M | $52.38M | $58.92M |
| Investing Cash Flow | ($86.83M) | ($5.32M) | ($18.25M) | ($777.0K) | ($133.0K) | ($5.19M) |
| Financing Cash Flow | ($6.21M) | ($28.39M) | ($37.87M) | ($24.23M) | ($88.12M) | $8.10M |
| CapEx | $178.0K | $323.0K | $747.0K | $777.0K | $133.0K | $4.44M |
| Free Cash Flow | $50.52M | $27.90M | $48.75M | $55.21M | $52.25M | $54.48M |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 73.0% | 81.6% | 82.1% | 77.3% | 81.1% | - |
| Operating margin | 25.6% | 1.6% | 17.5% | 11.1% | 19.3% | 31.3% |
| EBITDA margin | 25.8% | 2.1% | 18.0% | 11.6% | 19.9% | 31.7% |
| Net margin | 11.3% | -5.0% | 6.4% | 7.3% | 16.8% | 21.9% |
| Free cash flow margin | 16.0% | 16.3% | 26.0% | 28.2% | 27.6% | 23.0% |
| FCF / Net income | 1.42 | -3.23 | 4.07 | 3.86 | 1.64 | 1.05 |
| R&D / Revenue | 10.8% | 29.9% | 16.4% | 18.8% | 23.4% | 13.8% |
| SG&A / Revenue | 33.7% | 43.9% | 41.9% | 39.0% | 31.9% | 30.2% |
| Effective tax rate | 42.0% | - | 47.1% | 34.9% | 6.3% | 28.8% |
| Return on assets | 8.8% | -3.4% | 4.7% | 5.6% | 13.4% | 19.2% |
| Return on equity | 15.3% | -4.9% | 6.4% | 8.0% | 19.8% | 29.0% |
| Return on invested capital | 16.2% | 1.2% | 8.3% | 6.7% | 17.3% | 23.7% |
| Liquidity | ||||||
| Current ratio | 1.70 | 2.32 | 4.36 | 4.62 | 4.13 | 3.99 |
| Quick ratio | 1.27 | 2.03 | 4.15 | 4.45 | 3.92 | 3.88 |
| Cash ratio | 0.50 | 1.31 | 2.71 | 2.83 | 1.99 | 2.42 |
| Leverage | ||||||
| Debt / Equity | 0.24 | 0.00 | 0.14 | 0.19 | 0.24 | 0.24 |
| Debt / Assets | 0.14 | 0.00 | 0.10 | 0.13 | 0.16 | 0.16 |
| Debt / EBITDA | 0.69 | 0.00 | 0.74 | 1.47 | 1.01 | 0.57 |
| Interest coverage | 20.0x | 1.7x | 12.8x | 8.1x | 13.4x | 65.1x |
| Equity multiplier | 1.74 | 1.44 | 1.36 | 1.42 | 1.48 | 1.51 |
| Liabilities / Assets | 0.42 | 0.30 | 0.27 | 0.31 | - | - |
| Efficiency | ||||||
| Asset turnover | 0.78 | 0.68 | 0.74 | 0.77 | 0.79 | 0.88 |
| Inventory turnover | 1.79 | 1.44 | 4.17 | 7.29 | 4.31 | - |
| Days sales outstanding | 84d | 88d | 99d | 89d | 128d | 83d |
| Days inventory outstanding | 204d | 254d | 88d | 50d | 85d | - |
| Days payable outstanding | 81d | 190d | 68d | 42d | 101d | - |
| Cash conversion cycle | 207d | 151d | 119d | 98d | 112d | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 84.6% | -8.7% | -4.1% | 3.4% | -20.0% | 24.9% |
| Revenue CAGR (3y) | 17.4% | -3.3% | -7.4% | 1.1% | 42.0% | 353.4% |
| Revenue CAGR (5y) | 6.0% | -2.0% | 23.2% | 138.5% | - | - |
| Gross profit growth (YoY) | 65.1% | -9.2% | 1.8% | -1.5% | - | - |
| Operating income growth (YoY) | 2823.8% | -91.6% | 51.1% | -40.4% | -50.5% | 38.7% |
| Net income growth (YoY) | - | - | -16.2% | -55.1% | -38.6% | -36.2% |
| EPS growth (YoY) | - | - | -13.9% | -51.7% | -36.1% | -34.1% |
| EPS CAGR (3y) | 39.3% | - | -35.7% | -41.2% | - | - |
| EPS CAGR (5y) | -3.5% | - | - | - | - | - |
| FCF growth (YoY) | 81.1% | -42.8% | -11.7% | 5.7% | -4.1% | 5.6% |
| FCF CAGR (5y) | -1.5% | -11.6% | - | - | - | - |
| Book value growth (YoY) | 32.4% | -5.1% | 3.8% | 11.5% | -10.3% | 18.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$236.57M totalRoyalty$106.52M · 45.0%
Product$65.02M · 27.5%
Ryanodex$25.27M · 10.7%
Big Bagor Belrapzo$23.73M · 10.0%
Bendeka$11.17M · 4.7%
Other Product$4.86M · 2.1%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
2.34
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing EAGLE PHARMACEUTICALS against the 5 most active filers in the same SIC group.